The Top 3 Preclinical Considerations in the Discovery and Development of Novel Oncology Therapeutics

Summary: In this interview Kenneth J. Olivier Jr., PhD, Director of Toxicology at Merrimack Pharmaceuticals, speaks to Andrea Charles from Pharma IQ, about w hat trends he is witnessing in the improvement of safety assessments, his top 3 preclinical considerations in the